Plerixafor injection 24 mg/1.2 ml mainly is a hematopoietic stem cell mobilizer, helps bone marrow release stem cells in the bloodstream so they can be gathered and transplanted back into the body. The plerixafor injection 24 mg/1.2 ml is used in individuals with NHL (non-Hodgkin's lymphoma) or MM-multiple myeloma. Treatment with Plerixafor should be started after the patient has received G-CSF once daily for four days. Administer Plerixafor approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days. The recommended dosage of Plerixafor should be administered by subcutaneous injection and should be based on the body weight.